{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T03:00:51Z","timestamp":1784775651067,"version":"3.55.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"vor","delay-in-days":57,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Tianjin Health Research Project"},{"name":"Key Program of Tianjin Natural Science Foundation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nanobiotechnol"],"DOI":"10.1186\/s12951-026-04573-1","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T02:54:46Z","timestamp":1779850486000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Breaking bone-associated tumor vicious cycle through macrophage membrane-camouflaged nanodecoys for sonodynamic\/epigenetic therapeutics of oral squamous cell carcinoma"],"prefix":"10.1186","volume":"24","author":[{"given":"Mingxin","family":"Cao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuiyin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinming","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Sui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinsong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoying","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,27]]},"reference":[{"issue":"3","key":"4573_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"4573_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41368-023-00249-w","volume":"15","author":"Y Tan","year":"2023","unstructured":"Tan Y, Wang Z, Xu M, Li B, Huang Z, Qin S, et al. Oral squamous cell carcinomas: state of the field and emerging directions. Int J Oral Sci. 2023;15(1):44.","journal-title":"Int J Oral Sci"},{"key":"4573_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10123231","author":"YW Chen","year":"2022","unstructured":"Chen YW, Lin TR, Kuo PL, Lee SC, Wu KF, Duong TV, et al. Psychosocial adjustment changes and related factors in postoperative oral cancer patients: a longitudinal study. Biomedicines. 2022. https:\/\/doi.org\/10.3390\/biomedicines10123231.","journal-title":"Biomedicines"},{"issue":"10318","key":"4573_CR4","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1016\/S0140-6736(21)01550-6","volume":"398","author":"MD Mody","year":"2021","unstructured":"Mody MD, Rocco JW, Yom SS, Haddad RI, Saba NF. Head and neck cancer. Lancet. 2021;398(10318):2289\u201399.","journal-title":"Lancet"},{"key":"4573_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1640960","volume":"15","author":"Y Abouelkheer","year":"2025","unstructured":"Abouelkheer Y, Bhatia A. Head and neck cancer - emerging targeted therapies. Front Oncol. 2025;15:1640960.","journal-title":"Front Oncol"},{"issue":"1","key":"4573_CR6","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-025-01997-3","volume":"16","author":"L He","year":"2025","unstructured":"He L, Wan M, Yang X, Meng H. Distant metastasis of oral squamous cell carcinoma: immune escape mechanism and new perspectives on treatment. Discov Oncol. 2025;16(1):257.","journal-title":"Discov Oncol"},{"issue":"9","key":"4573_CR7","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1016\/j.jcms.2017.04.012","volume":"45","author":"LAA Vaassen","year":"2017","unstructured":"Vaassen LAA, Speel EM, Kessler P. Bone invasion by oral squamous cell carcinoma: molecular alterations leading to osteoclastogenesis - a review of literature. J Craniomaxillofac Surg. 2017;45(9):1464\u201371.","journal-title":"J Craniomaxillofac Surg"},{"issue":"8","key":"4573_CR8","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1038\/nrc867","volume":"2","author":"GR Mundy","year":"2002","unstructured":"Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer. 2002;2(8):584\u201393.","journal-title":"Nat Rev Cancer"},{"issue":"7","key":"4573_CR9","doi-asserted-by":"publisher","first-page":"2713","DOI":"10.1158\/1078-0432.CCR-04-1767","volume":"11","author":"N Cui","year":"2005","unstructured":"Cui N, Nomura T, Noma H, Yokoo K, Takagi R, Hashimoto S, et al. Effect of YM529 on a model of mandibular invasion by oral squamous cell carcinoma in mice. Clin Cancer Res. 2005;11(7):2713\u20139.","journal-title":"Clin Cancer Res"},{"key":"4573_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2025.115696","volume":"226","author":"P Cressey","year":"2025","unstructured":"Cressey P, Abd Shukor SB, Thanou M. Sonodynamic therapy: transforming sound into light for hard-to-treat tumours. Adv Drug Deliv Rev. 2025;226:115696.","journal-title":"Adv Drug Deliv Rev"},{"key":"4573_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.pmatsci.2025.101634","volume":"158","author":"S Ghosh","year":"2025","unstructured":"Ghosh S, Yang C-J, Lai J-Y. Hollow nanoarchitectures: materials engineering, nanochemistry, and biomedical applications. Prog Mater Sci. 2025;158:101634.","journal-title":"Prog Mater Sci"},{"issue":"30","key":"4573_CR12","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202505310","volume":"12","author":"M Yang","year":"2025","unstructured":"Yang M, Meng Y, Li J, Bai L, Cheng Y, Liu Y, et al. Nanofabricated bacterial cell walls with intrinsic peroxidase-mimicking and sonodynamic activities for cancer combination treatment. Adv Sci (Weinh). 2025;12(30):e2505310.","journal-title":"Adv Sci (Weinh)"},{"key":"4573_CR13","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.actbio.2024.03.019","volume":"179","author":"S Ghosh","year":"2024","unstructured":"Ghosh S, Lai J-Y. An insight into the dual role of MoS2-based nanocarriers in anticancer drug delivery and therapy. Acta Biomater. 2024;179:36\u201360.","journal-title":"Acta Biomater"},{"issue":"5","key":"4573_CR14","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1111\/cas.13578","volume":"109","author":"Q Zhang","year":"2018","unstructured":"Zhang Q, Bao C, Cai X, Jin L, Sun L, Lang Y, et al. Sonodynamic therapy-assisted immunotherapy: a novel modality for cancer treatment. Cancer Sci. 2018;109(5):1330\u201345.","journal-title":"Cancer Sci"},{"issue":"47","key":"4573_CR15","doi-asserted-by":"publisher","first-page":"11265","DOI":"10.1039\/D3TB02046K","volume":"11","author":"Q Chen","year":"2023","unstructured":"Chen Q, Shan T, Liang Y, Xu Y, Shi E, Wang Y, et al. A biomimetic phototherapeutic nanoagent based on bacterial double-layered membrane vesicles for comprehensive treatment of oral squamous cell carcinoma. J Mater Chem B. 2023;11(47):11265\u201379.","journal-title":"J Mater Chem B"},{"key":"4573_CR16","volume":"2010","author":"A Duray","year":"2010","unstructured":"Duray A, Demoulin S, Hubert P, Delvenne P, Saussez S. Immune suppression in head and neck cancers: a review. Clin Dev Immunol. 2010;2010:701657.","journal-title":"Clin Dev Immunol"},{"key":"4573_CR17","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.coi.2015.12.007","volume":"39","author":"F Garrido","year":"2016","unstructured":"Garrido F, Aptsiauri N, Doorduijn EM, Garcia Lora AM, van Hall T. The urgent need to recover MHC class I in cancers for effective immunotherapy. Curr Opin Immunol. 2016;39:44\u201351.","journal-title":"Curr Opin Immunol"},{"issue":"2","key":"4573_CR18","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1385\/IR:33:2:113","volume":"33","author":"RL Ferris","year":"2005","unstructured":"Ferris RL, Hunt JL, Ferrone S. Human leukocyte antigen (HLA) class I defects in head and neck cancer: molecular mechanisms and clinical significance. Immunol Res. 2005;33(2):113\u201333.","journal-title":"Immunol Res"},{"issue":"5","key":"4573_CR19","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/nrc.2018.11","volume":"18","author":"CR Leemans","year":"2018","unstructured":"Leemans CR, Snijders PJF, Brakenhoff RH. The molecular landscape of head and neck cancer. Nat Rev Cancer. 2018;18(5):269\u201382.","journal-title":"Nat Rev Cancer"},{"issue":"10212","key":"4573_CR20","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","volume":"394","author":"B Burtness","year":"2019","unstructured":"Burtness B, Harrington KJ, Greil R, Souli\u00e8res D, Tahara M, de Castro G Jr, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet. 2019;394(10212):1915\u201328.","journal-title":"Lancet"},{"key":"4573_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12071760","author":"AM Cornel","year":"2020","unstructured":"Cornel AM, Mimpen IL, Nierkens S. MHC Class I downregulation in cancer: underlying mechanisms and potential targets for cancer immunotherapy. Cancers (Basel). 2020. https:\/\/doi.org\/10.3390\/cancers12071760.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"4573_CR22","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1158\/1078-0432.CCR-19-1351","volume":"26","author":"L Zhou","year":"2020","unstructured":"Zhou L, Mudianto T, Ma X, Riley R, Uppaluri R. Targeting EZH2 enhances antigen presentation, antitumor immunity, and circumvents Anti-PD-1 resistance in head and neck cancer. Clin Cancer Res. 2020;26(1):290\u2013300.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"4573_CR23","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.ccell.2019.08.008","volume":"36","author":"ML Burr","year":"2019","unstructured":"Burr ML, Sparbier CE, Chan KL, Chan YC, Kersbergen A, Lam EYN, et al. An evolutionarily conserved function of polycomb silences the MHC class I antigen presentation pathway and enables immune evasion in cancer. Cancer Cell. 2019;36(4):385-401.e8.","journal-title":"Cancer Cell"},{"issue":"4","key":"4573_CR24","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1038\/s43018-021-00185-w","volume":"2","author":"KL Morel","year":"2021","unstructured":"Morel KL, Sheahan AV, Burkhart DL, Baca SC, Boufaied N, Liu Y, et al. EZH2 inhibition activates a dsRNA-STING-interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer. Nat Cancer. 2021;2(4):444\u201356.","journal-title":"Nat Cancer"},{"issue":"9","key":"4573_CR25","doi-asserted-by":"publisher","first-page":"3813","DOI":"10.1172\/JCI99760","volume":"128","author":"S Goswami","year":"2018","unstructured":"Goswami S, Apostolou I, Zhang J, Skepner J, Anandhan S, Zhang X, et al. Modulation of EZH2 expression in T cells improves efficacy of anti-CTLA-4 therapy. J Clin Invest. 2018;128(9):3813\u20138.","journal-title":"J Clin Invest"},{"issue":"20","key":"4573_CR26","doi-asserted-by":"publisher","first-page":"3901","DOI":"10.1016\/j.molcel.2022.09.007","volume":"82","author":"Y Li","year":"2022","unstructured":"Li Y, Goldberg EM, Chen X, Xu X, McGuire JT, Leuzzi G, et al. Histone methylation antagonism drives tumor immune evasion in squamous cell carcinomas. Mol Cell. 2022;82(20):3901-18.e7.","journal-title":"Mol Cell"},{"issue":"11","key":"4573_CR27","doi-asserted-by":"publisher","first-page":"4452","DOI":"10.4049\/jimmunol.1501466","volume":"196","author":"C Fang","year":"2016","unstructured":"Fang C, Qiao Y, Mun SH, Lee MJ, Murata K, Bae S, et al. Cutting edge: EZH2 promotes osteoclastogenesis by epigenetic silencing of the negative regulator IRF8. J Immunol. 2016;196(11):4452\u20136.","journal-title":"J Immunol"},{"issue":"1","key":"4573_CR28","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1002\/jbmr.3863","volume":"35","author":"J Adamik","year":"2020","unstructured":"Adamik J, Pulugulla SH, Zhang P, Sun Q, Lontos K, Macar DA, et al. EZH2 supports osteoclast differentiation and bone resorption via epigenetic and cytoplasmic targets. J Bone Miner Res. 2020;35(1):181\u201395.","journal-title":"J Bone Miner Res"},{"issue":"5","key":"4573_CR29","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1111\/jop.12376","volume":"45","author":"R Tohyama","year":"2016","unstructured":"Tohyama R, Kayamori K, Sato K, Hamagaki M, Sakamoto K, Yasuda H, et al. Establishment of a xenograft model to explore the mechanism of bone destruction by human oral cancers and its application to analysis of role of RANKL. J Oral Pathol Med. 2016;45(5):356\u201364.","journal-title":"J Oral Pathol Med"},{"issue":"11","key":"4573_CR30","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.tem.2012.05.005","volume":"23","author":"T Nakashima","year":"2012","unstructured":"Nakashima T, Hayashi M, Takayanagi H. New insights into osteoclastogenic signaling mechanisms. Trends Endocrinol Metab. 2012;23(11):582\u201390.","journal-title":"Trends Endocrinol Metab"},{"issue":"12","key":"4573_CR31","doi-asserted-by":"publisher","DOI":"10.1002\/smll.202106568","volume":"18","author":"A Zhou","year":"2022","unstructured":"Zhou A, Fang T, Chen K, Xu Y, Chen Z, Ning X. Biomimetic activator of sonodynamic ferroptosis amplifies inherent peroxidation for improving the treatment of breast cancer. Small. 2022;18(12):e2106568.","journal-title":"Small"},{"issue":"3","key":"4573_CR32","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.ccell.2025.01.013","volume":"43","author":"P Porazzi","year":"2025","unstructured":"Porazzi P, Nason S, Yang Z, Carturan A, Ghilardi G, Guruprasad P, et al. EZH1\/EZH2 inhibition enhances adoptive T cell immunotherapy against multiple cancer models. Cancer Cell. 2025;43(3):537-51.e7.","journal-title":"Cancer Cell"},{"key":"4573_CR33","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17030437","author":"PJ Oppelt","year":"2025","unstructured":"Oppelt PJ, Puram SV, Liu J, Ley JC, Adkins D. Tazemetostat, a selective EZH2 inhibitor, in combination with pembrolizumab for recurrent or metastatic head and neck squamous cell carcinoma: a phase 1 trial. Cancers (Basel). 2025. https:\/\/doi.org\/10.3390\/cancers17030437.","journal-title":"Cancers (Basel)"},{"issue":"9","key":"4573_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2023.105155","volume":"299","author":"ME Carrasco","year":"2023","unstructured":"Carrasco ME, Thaler R, Nardocci G, Dudakovic A, van Wijnen AJ. Inhibition of Ezh2 redistributes bivalent domains within transcriptional regulators associated with WNT and Hedgehog pathways in osteoblasts. J Biol Chem. 2023;299(9):105155.","journal-title":"J Biol Chem"},{"key":"4573_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2022.121952","volume":"293","author":"L Zhao","year":"2023","unstructured":"Zhao L, Rao X, Huang C, Zheng R, Kong R, Chen Z, et al. Epigenetic reprogramming of carrier free photodynamic modulator to activate tumor immunotherapy by EZH2 inhibition. Biomaterials. 2023;293:121952.","journal-title":"Biomaterials"},{"issue":"8","key":"4573_CR36","doi-asserted-by":"publisher","DOI":"10.1002\/smtd.202200289","volume":"6","author":"J Lopes","year":"2022","unstructured":"Lopes J, Lopes D, Pereira-Silva M, Peixoto D, Veiga F, Hamblin MR, et al. Macrophage cell membrane-cloaked nanoplatforms for biomedical applications. Small Methods. 2022;6(8):e2200289.","journal-title":"Small Methods"},{"issue":"1","key":"4573_CR37","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1021\/acsnano.2c07861","volume":"17","author":"J Li","year":"2023","unstructured":"Li J, Wu Y, Wang J, Xu X, Zhang A, Li Y, et al. Macrophage membrane-coated nano-gemcitabine promotes lymphocyte Infiltration and synergizes AntiPD-L1 to restore the tumoricidal function. ACS Nano. 2023;17(1):322\u201336.","journal-title":"ACS Nano"},{"issue":"48","key":"4573_CR38","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abl6432","volume":"7","author":"Y Zhou","year":"2021","unstructured":"Zhou Y, Deng Y, Liu Z, Yin M, Hou M, Zhao Z, et al. Cytokine-scavenging nanodecoys reconstruct osteoclast\/osteoblast balance toward the treatment of postmenopausal osteoporosis. Sci Adv. 2021;7(48):eabl6432.","journal-title":"Sci Adv"},{"key":"4573_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.nantod.2022.101587","volume":"46","author":"Z Guo","year":"2022","unstructured":"Guo Z, Xin Y, Yang L, Ran R, Wan G, Ma A, et al. Biomimetic nanotherapeutics based on oxygen supply and ultrasmall Cu-Se-Au alloy nanoparticles for boosting radio-photothermal ablation of breast cancer. Nano Today. 2022;46:101587.","journal-title":"Nano Today"},{"key":"4573_CR40","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics16111383","author":"KA Al Refaai","year":"2024","unstructured":"Al Refaai KA, Al Sawaftah NA, Abuwatfa W, Husseini GA. Drug release via ultrasound-activated nanocarriers for cancer treatment: a review. Pharmaceutics. 2024. https:\/\/doi.org\/10.3390\/pharmaceutics16111383.","journal-title":"Pharmaceutics"},{"issue":"26","key":"4573_CR41","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202302174","volume":"10","author":"CJ Yang","year":"2023","unstructured":"Yang CJ, Nguyen DD, Lai JY. Poly(l-Histidine)-mediated on-demand therapeutic delivery of roughened ceria nanocages for treatment of chemical eye injury. Adv Sci (Weinh). 2023;10(26):e2302174.","journal-title":"Adv Sci (Weinh)"},{"issue":"1","key":"4573_CR42","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1021\/acsnano.2c05824","volume":"17","author":"DD Nguyen","year":"2023","unstructured":"Nguyen DD, Luo L-J, Yang C-J, Lai J-Y. Highly retina-permeating and long-acting resveratrol\/metformin nanotherapeutics for enhanced treatment of macular degeneration. ACS Nano. 2023;17(1):168\u201383.","journal-title":"ACS Nano"},{"key":"4573_CR43","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/978-1-60761-411-1_4","volume":"594","author":"E Eruslanov","year":"2010","unstructured":"Eruslanov E, Kusmartsev S. Identification of ROS using oxidized DCFDA and flow-cytometry. Methods Mol Biol. 2010;594:57\u201372.","journal-title":"Methods Mol Biol"},{"issue":"5","key":"4573_CR44","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.ultrasmedbio.2025.01.011","volume":"51","author":"T Wang","year":"2025","unstructured":"Wang T, Du M, Chen Z. Sonosensitizers for sonodynamic therapy: current progress and future perspectives. Ultrasound Med Biol. 2025;51(5):727\u201334.","journal-title":"Ultrasound Med Biol"},{"key":"4573_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.foodchem.2022.133584","volume":"395","author":"X Zheng","year":"2022","unstructured":"Zheng X, Huang Q. Assessment of the antioxidant activities of representative optical and geometric isomers of astaxanthin against singlet oxygen in solution by a spectroscopic approach. Food Chem. 2022;395:133584.","journal-title":"Food Chem"},{"issue":"11","key":"4573_CR46","first-page":"3865","volume":"6","author":"T Zhang","year":"2021","unstructured":"Zhang T, Liu H, Li L, Guo Z, Song J, Yang X, et al. Leukocyte\/platelet hybrid membrane-camouflaged dendritic large pore mesoporous silica nanoparticles co-loaded with photo\/chemotherapeutic agents for triple negative breast cancer combination treatment. Bioact Mater. 2021;6(11):3865\u201378.","journal-title":"Bioact Mater"},{"issue":"2","key":"4573_CR47","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202204365","volume":"10","author":"Y Yang","year":"2023","unstructured":"Yang Y, Huang J, Liu M, Qiu Y, Chen Q, Zhao T, et al. Emerging sonodynamic therapy-based nanomedicines for cancer immunotherapy. Adv Sci (Weinh). 2023;10(2):e2204365.","journal-title":"Adv Sci (Weinh)"},{"key":"4573_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2023.109772","volume":"256","author":"Y Zhou","year":"2023","unstructured":"Zhou Y, Jiao J, Yang R, Wen B, Wu Q, Xu L, et al. Temozolomide-based sonodynamic therapy induces immunogenic cell death in glioma. Clin Immunol. 2023;256:109772.","journal-title":"Clin Immunol"},{"issue":"12","key":"4573_CR49","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1038\/nrc3380","volume":"12","author":"DV Krysko","year":"2012","unstructured":"Krysko DV, Garg AD, Kaczmarek A, Krysko O, Agostinis P, Vandenabeele P. Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer. 2012;12(12):860\u201375.","journal-title":"Nat Rev Cancer"},{"key":"4573_CR50","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.actbio.2024.07.027","volume":"186","author":"L Bai","year":"2024","unstructured":"Bai L, Yang M, Wu J, You R, Chen Q, Cheng Y, et al. An injectable adhesive hydrogel for photothermal ablation and antitumor immune activation against bacteria-associated oral squamous cell carcinoma. Acta Biomater. 2024;186:229\u201345.","journal-title":"Acta Biomater"},{"key":"4573_CR51","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/978-1-0716-0896-8_17","volume":"2202","author":"SK Sharma","year":"2021","unstructured":"Sharma SK, Hamblin MR. The use of fluorescent probes to detect ROS in photodynamic therapy. Methods Mol Biol. 2021;2202:215\u201329.","journal-title":"Methods Mol Biol"}],"container-title":["Journal of Nanobiotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12951-026-04573-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-026-04573-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-026-04573-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T02:02:00Z","timestamp":1784772120000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12951-026-04573-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,27]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4573"],"URL":"https:\/\/doi.org\/10.1186\/s12951-026-04573-1","relation":{},"ISSN":["1477-3155"],"issn-type":[{"value":"1477-3155","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,27]]},"assertion":[{"value":"23 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All animal experiments were approved by the Animal Care and Use Committee of Yi Shengyuan Gene Technology (YSY-DWLL-2024409) in accordance with the National Institutes of Health guidelines.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors have read and approved this version of the article for publication.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"690"}}